X0508 4 2026-01-22 0001842295 Maze Therapeutics, Inc. MAZE 0002050422 Bachrodt Amy C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 false true false false SVP, Finance 1 Common Stock 2026-01-22 4 M 0 2497 10.42 A 15462 D Common Stock 2026-01-22 4 M 0 2503 10.42 A 17965 D Common Stock 2026-01-22 4 S 0 5000 45.5224 D 12965 D Stock Option (Right to Buy) 10.42 2026-01-22 4 M 0 2497 0 D 2031-03-03 Common Stock 2497 486 D Stock Option (Right to Buy) 10.42 2026-01-22 4 M 0 2503 0 D 2032-02-17 Common Stock 2503 7869 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.93 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2021, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on March 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. /s/ Courtney Phillips, as attorney-in-fact 2026-01-26